Oxford Instruments PLC Sale of Minority Share in Scienta Omicron (2202B)
29 Gennaio 2020 - 8:00AM
UK Regulatory
TIDMOXIG
RNS Number : 2202B
Oxford Instruments PLC
29 January 2020
Oxford Instruments plc
Sale of Minority Share in Scienta Omicron
Oxford, 29 January 2020
Oxford Instruments plc, a leading provider of high technology
products and services to industrial companies and scientific
research communities, today announces that it has completed the
sale of its 47% share in Scienta Omicron to a group of existing
shareholders in the joint venture for a consideration of SEK 147
million (GBP11.7 million).
The joint venture was established in 2015 consisting of Oxford
Instruments' Omicron Nanotechnology GmBH and GDI's Scienta
Scientific, creating a leading company in Ultra High Vacuum Surface
Science.
Ian Barkshire, Chief Executive of Oxford Instruments said, "The
sale of our share in Scienta Omicron supports our continued
customer-centric focus on our chosen markets with long-term growth
drivers where we can maintain or develop leading positions,
enhancing our ability to deliver further growth and margin
improvement."
-END-
Enquiries:
Oxford Instruments plc Tel: 01865 393200
Ian Barkshire, Chief Executive
Gavin Hill, Group Finance Director
MHP Communications Tel: 020 3128 8100
Rachel Hirst/Alice McLaren
- Ends -
Issued for and on behalf of Oxford Instruments plc
Notes to Editors
About Oxford Instruments plc
Oxford Instruments designs, supplies and supports
high-technology tools and systems with a focus on research and
industrial applications. Innovation has been the driving force
behind Oxford Instruments' growth and success for 60 years,
supporting its core purpose to address some of the world's most
pressing challenges.
The first technology business to be spun out from Oxford
University, Oxford Instruments is now a global company and is
listed on the London Stock Exchange (OXIG). Its strategy focuses on
being a customer-centric, market-focused Group, understanding the
technical and commercial challenges faced by its customers. Key
market segments include Semiconductor & Communications,
Advanced Materials, Healthcare & Life Science, and Quantum
Technology.
Their portfolio includes a range of core technologies in areas
such as low temperature and high magnetic field environments;
Nuclear Magnetic Resonance; X-ray, electron, laser and optical
based metrology; atomic force microscopy; optical imaging; and
advanced growth, deposition and etching.
Oxford Instruments is helping enable a greener economy,
increased connectivity, improved health and leaps in scientific
understanding. Their advanced products and services allow the
world's leading industrial companies and scientific research
communities to image, analyse and manipulate materials down to the
atomic and molecular level, helping to accelerate R&D, increase
manufacturing productivity and make ground breaking
discoveries.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DISEANFPAEDEEFA
(END) Dow Jones Newswires
January 29, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Oxford Instruments (LSE:OXIG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxford Instruments (LSE:OXIG)
Storico
Da Apr 2023 a Apr 2024